Mission Pharmacal Co.

Mission Pharmacal Co.

Mission Pharmacal Co.

Overview
Date Founded

1946

Headquarters

10999 Interstate Highway 10 West,Suite 1000,San Antonio, TX 78230-1355

Type of Company

Private

Industries

Pharmaceuticals

Company Description

Mission Pharmacal Co. manufactures pharmaceutical products. Its products include Flowtuss, Hycofenix, Thera-Gesic, Oncovite, Maxilube, Heat Guard, Foseree and Texacort. The company’s capabilities include research and development, laboratory, manufacturing, packaging, warehousing and distribution and international services. Mission Pharmacal was founded in 1946 by H. N. Walsdorf and is headquartered in San Antonio, TX.

Executives & Employees

Founder

President & Chief Executive Officer

Chairman

Executive Director, Dermatology Consumer Esthetics

Chief Financial Officer

Chief Operating Officer

Vice President, General Manager, Mission Dermatology

General Manager

President, Commercial Operations

Senior Director

Board of Directors

Former Chief Executive Officer at Mission Pharmacal Co.

Paths to Mission Pharmacal Co.
Potential Connections via
Relationship Science
You
Mission Pharmacal Co.
Recent Transactions
Details Hidden

Mission Pharmacal Co., Espada Dermatology, Inc. purchase Lautus Pharmaceuticals LLC /GlyDerm from Lautus Pharmaceuticals LLC

Details Hidden

Mission Pharmacal Co., BexR Logistix LLC purchase EPIC Fulfillment, Inc.

Details Hidden

Mission Pharmacal Co. purchases ProSolus Pharmaceuticals LP

Clients

Retrophin, Inc. is a biopharmaceutical company, which engages in identifying, developing, and delivering therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Midatech Pharma Plc commercializes oncology treatments and cancer supportive care products through its U.S. commercial organization, Midatech Pharma US. The firm engages in the development of pharmaceutical products utilizing its nanomedicine and sustained release technologies. It operates through Pipeline Research & Development and Commercial segments. The Pipeline Research & Development segment seeks to develop products using nanomedicine and sustained release technology platforms. The Commercial segment distributes and sells commercial products. The company was founded on September 12, 2014 and is headquartered in Abingdon, the United Kingdom.

Non-Profit Donations & Grants
$5,000 - $10K
2013
$1,000 - $4,999
2011
$1,000 - $2,499
2011